Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, briefly discusses the value of measurable residual disease (MRD) status in predicting the outcomes of patients with chronic lymphocytic leukemia (CLL) treated with time-limited targeted therapies and chemoimmunotherapy (CIT). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть